Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Engineered TILs/CAR-TILs in Advanced Solid Tumors
NCT04842812Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Jan 2021
- Primary completion
- Dec 2029
- Modality
- CRISPR-Cas9, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of engineered TILs/CAR-TILs in solid tumor, sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Safety of TILs/CAR-TILs treatment in advanced solid cancers at 36 months. Started Jan 2021; status: recruiting.
02
Drugs
engineered TILs/CAR-TILs
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04842812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04842812.